What is the Cystic Fibrosis Market Forecast?
What is the Cystic Fibrosis Market?
DelveInsight’s ‘Cystic Fibrosis Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Cystic Fibrosis, historical and forecasted epidemiology as well as the Cystic Fibrosis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
What is the Cystic Fibrosis Market Size Report?
The Cystic Fibrosis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Cystic Fibrosis market size from 2019 to 2032. The Report also covers current Cystic Fibrosis treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
What is the Cystic Fibrosis Epidemiology?
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Cystic Fibrosis, Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis, Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis, Type-specific Diagnosed Prevalent Cases of Cystic Fibrosis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
What is the Cystic Fibrosis Emerging Drugs?
VX-121/TEZ/ VX-561: Vertex Pharmaceuticals
VX-121 is an orally administered CFTR corrector that helps fix and restore the function of defective CFTR protein. The corrected CFTR protein can then translocate to the cell surface where it performs the normal function and helps maintain the right balance of fluid in the airways.
VX-561 is an orally administered CFTR potentiator that helps restore the function of defective CFTR protein. It is the deuterated, or deuterium-modified form of Kalydeco (ivacaftor) used for CF patients with gating mutations (e.g., G551D) of the gene that encodes for the CFTR protein. It helps keep the channel open for the molecules to pass through and allows them to maintain the proper ion and fluid balance.
Ensifentrine: Verona Pharmaceuticals
Ensifentrine (RPL554) is a first-in-class, inhaled, dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes, and Verona Pharma’s lead pipeline asset. This dual inhibition enables it to combine bronchodilator and anti-inflammatory properties in one compound, differentiating it from existing drug classes used to treat COPD, including corticosteroids, beta2-agonists, and anti-muscarinic.
What about Cystic Fibrosis Market Outlook?
Cystic fibrosis (CF) is an autosomal recessive genetic disorder that causes damage to the lungs and the digestive system with the highest prevalence in Europe, North America. This disease is caused by a genetic mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR protein is a chloride-conducting trans-membrane conductance regulator belonging to the ABC transporter class which helps in the transportation of chloride ions which helps to maintain the electrochemical gradient as well as osmotic and fluid balance in the passageways.People with cystic fibrosis have difficulty in breathing and suffer from bronchospasms. Hence bronchodilators are administered to them to relax the smooth muscles of airways and aid in respiration. Albuterol which is marketed as Ventolin, is the most commonly used broncho-dilating agent that provides selective agonistic action on beta2-adrenoceptors.Cystic Fibrosis is associated with inflammation. As a result of which large amounts of neutrophil-derived DNA are released in the sputum which increases its viscosity. Mucolytics, such as dornase alfa, is therefore used that hydrolyze the DNA. Dornase alfa (Pulmozyme) is a recombinant human DNase (rhDNase) which helps hydrolyze the DNA as a result of which the proteolytic enzymes can break down the proteins decreasing viscoelasticity and surface tension of purulent sputum.
Source- Cystic Fibrosis Market Companies
Trending Market Research Reports in 2023
- Lactose Intolerance Market
- Shingles Market
- Persistent Epithelial Defect Market
- Oncolytic Virus Cancer Therapy Pipeline
- Stem Cell Market
- Vital Sign Monitors Devices Market
- Radiation Retinopathy Market
- Pelizaeus-Merzbacher Disease Market
- Adult T-Cell Leukemia-Lymphoma Market
- Drug Resistant Epilepsy Market
- Hypoxic Ischemic Encephalopathy Market
- Myopia Progression Market
- Ptosis Market
- Tay-Sachs Disease Market
- Cannabis Use Disorder Market
- Myocardial Infarction Market
- Diabetes Insipidus Market
- Kawasaki Disease Market
- Chagas Disease Market
- Glioblastoma Multiforme Market
- Polycystic Kidney Disease Market
- Uterine Leiomyoma (Uterine Fibroids) Market
- Meningococcal Meningitis Market
- Radiodermatitis Market
- Intraocular Lens Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
Comments
Post a Comment